Ishikawa T, Takemoto M, Akimoto Y, Takada-Watanabe A, Yan K, Sakamoto K, Maezawa Y, Suguro M, He L, Tryggvason K, Betsholtz C, Yokote K. A novel podocyte protein, R3h domain containing-like, inhibits TGF-β-induced p38 MAPK and regulates the structure of podocytes and glomerular basement membrane. J Mol Med(Berl). 2021 Feb 23. doi: 10.1007/s00109-021-02050-w. Epub ahead of print. PMID:33620517.
【ニュースリリース】 竹本主任教授の研究グループが糖尿病腎症の発症に関わる新しい遺伝子の解析結果を発表しました。
Koshizaka M, Maezawa Y, Maeda Y, Shoji M, Kato H, Kaneko H, Ishikawa T, Kinoshita D, Kobayashi K, Kawashima J, Sekiguchi A, Motegi SI, Nakagami H, Yamada Y, Tsukamoto S, Taniguchi A, Sugimoto K, Shoda Y, Hashimoto K, Yoshimura T, Suzuki D, Kuzuya M, Takemoto M, Yokote K. Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. Aging (Albany NY). 2020 Dec 29;12(24):24940-24956. doi: 10.18632/aging.202441. Epub 2020 Dec 29. PMID: 33373317; PMCID: PMC7803551.
Taniguchi A, Tanaka Y, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Mori S, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020 8. Calcification in tendons associated with Werner syndrome. Geriatr Gerontol Int. 2021 Feb;21(2):163-165. doi: 10.1111/ggi.14084. Epub 2020 Dec 1. PMID: 33260264.
Tsukamoto K, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome. Geriatr Gerontol Int. 2021 Feb;21(2):133-138. doi: 10.1111/ggi.14095. Epub 2020 Dec 1. PMID: 33258561.
【ニュースリリース】世界初 竹本稔主任教授を中心とする研究グループが、遺伝性早老症ウェルナー症候群の診療ガイドラインを発表
Kubota Y, Takemoto M, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Tsukamoto K, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020. 6. Skin ulcers associated with Werner syndrome: Prevention and non-surgical and surgical treatment. Geriatr Gerontol Int. 2021 Feb;21(2):153-159. doi: 10.1111/ggi.14096. Epub 2020 Nov 22. PMID: 33225552.
Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Mori S, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome. Geriatr Gerontol Int. 2021 Feb;21(2):142-145. doi: 10.1111/ggi.14083. Epub 2020 Nov 9. PMID: 33169495.
Kuzuya M, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Tsukamoto K, Yokote K. Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome. Geriatr Gerontol Int. 2021 Feb;21(2):139-141. doi: 10.1111/ggi.14076. Epub 2020 Nov 9. PMID: 33169468.
Mori S, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020. 4. Osteoporosis associated with Werner syndrome. Geriatr Gerontol Int. 2021 Feb;21(2):146-149. doi: 10.1111/ggi.14078. Epub 2020 Nov 5. PMID: 33155383.
Motegi SI, Takemoto M, Taniguchi T, Kubota Y, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Tsukamoto K, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020. 7. Skin ulcer associated with Werner syndrome: Dermatological treatment. Geriatr Gerontol Int. 2021 Feb;21(2):160-162. doi: 10.1111/ggi.14077. Epub 2020 Nov 3. PMID: 33142357.
Takemoto M, Yokote K. Preface to Management guideline for Werner syndrome 2020. Geriatr Gerontol Int. 2021 Feb;21(2):131-132. doi: 10.1111/ggi.14074. Epub2020 Oct 29. PMID: 33118681.
プレスリリース
Koshizaka M, Ishikawa K, Ishibashi R, Takahashi S, Sakamoto K, Yokoh H, BabaY, Ide S, Ide K, Ishikawa T, Onishi S, Kobayashi K, Takemoto M, Horikoshi T,Shimofusa R, Maezawa Y, Yokote K. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study. Diabetes Ther. 2021 Jan;12(1):183-196. doi: 10.1007/s13300-020-00949-0. Epub 2020 Oct 24. PMID: 33098565; PMCID: PMC7843837.
Li SY, Yoshida Y, Kobayashi E, Adachi A, Hirono S, Matsutani T, Mine S, Machida T, Ohno M, Nishi E, Maezawa Y, Takemoto M, Yokote K, Kitamura K, Sumazaki M, Ito M, Shimada H, Takizawa H, Kashiwado K, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda H, Zhang XM, Wang H, Goto K, Iwadate Y, Hiwasa T. Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. Int J Mol Med. 2020 Oct;46(4):1274-1288. doi: 10.3892/ijmm.2020.4690. Epub 2020 Jul 29. PMID: 32945427; PMCID: PMC7447314.
Sumazaki M, Shimada H, Ito M, Shiratori F, Kobayashi E, Yoshida Y, Adachi A,Matsutani T, Iwadate Y, Mine S, Machida T, Kamitsukasa I, Mori M, Sugimoto K,Uzawa A, Kuwabara S, Kobayashi Y, Ohno M, Nishi E, Maezawa Y, Takemoto M, Yokote K, Takizawa H, Kashiwado K, Shin H, Kishimoto T, Matsushita K, Kobayashi S,Nakamura R, Shinmen N, Kuroda H, Zhang XM, Wang H, Goto KI, Hiwasa T. Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Sci. 2020 Dec;111(12):4453-4464. doi: 10.1111/cas.14652. Epub 2020 Oct 4. PMID: 32939876; PMCID: PMC7734161.
Yoshida Y, Zhang XM, Wang H, Machida T, Mine S, Kobayashi E, Adachi A, Matsutani T, Kamitsukasa I, Wada T, Aotsuka A, Iwase K, Tomiyoshi G, Nakamura R,Shinmen N, Kuroda H, Takizawa H, Kashiwado K, Shin H, Akaogi Y, Shimada J, Nishi E, Ohno M, Takemoto M, Yokote K, Kitamura K, Iwadate Y, Hiwasa T. Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. Heliyon. 2020 Aug 19;6(8):e04661. doi: 10.1016/j.heliyon.2020.e04661.PMID: 32904265; PMCID: PMC7452465.
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K,Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V study group. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study). J Diabetes Investig.2021 Feb;12(2):200-206. doi: 10.1111/jdi.13340. Epub 2020 Aug 20. PMID:32623839; PMCID: PMC7858125.
Ishida A, Igarashi K, Ruike Y, Ishiwata K, Naito K, Kono S, Deguchi H, Fujimoto M, Shiga A, Suzuki S, Yoshida T, Tanaka T, Tatsuno I, Yokote K, Koide H. Association of urinary free cortisol with bone formation in patients with mild autonomous cortisol secretion. Clin Endocrinol (Oxf). 2020.
Ohira M, Suzuki S, Yoshida T, Koide H, Tanaka T, Tatsuno I. Fracture Risk Assessment Tool May Not Indicate Bone Fragility in Women With Type 2 Diabetes. Am J Med Sci. 2020;360(5):552-559.
Yoshida T, Takemoto M. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. J Diabetes Investig. 2021;12(3):454-458.